Chairman, President, and Chief Executive Officer
United States of America
Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer, and was appointed Chairman of the Board of Directors in 2015. Prior to joining Incyte, Mr Hoppenot was the President of Novartis Oncology, where he was responsible for translational medicine, development, approval, and commercialization, which included $11 billion in global sales, the largest oncology pipeline in the industry, and 8000 employees in 50 countries. Mr Hoppenot joined Novartis in 2003, and, in addition to his role as President, served as Chief Commercial Officer, Head of Global Product Strategy & Scientific Development, and Senior Vice President, Head of Global Marketing. He started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the US Oncology business unit. Mr Hoppenot holds a diploma from ESSEC Business School.